

Curriculum Vitae

In-San Kim, MD, Ph.D.

Education and Training

1986-1989	D. Med. Sci (Ph.D) Kyungpook National University, Korea
1984-1986	M. Med. Sci (MS) Kyungpook National University, Korea
1978-1984	B. Med (MD) in School of Medicine Kyungpook National University, Korea
1997-1997	Visiting assistant professor , Department of Molecular Genetics University of Texas M. D. Anderson Cancer Center
1994-1996	Research Associate , Department of Molecular Genetics, University of Texas M. D. Anderson Cancer Center
1993-1993	Research fellowship , Department of Dermatology, Jefferson Medical College

Professional Experiences

2015-present	Professor, KU-KIST school, Korea University
2014-Present	Principal research scientist, Korea Institute Science & Technology
1989-2014	Professor , Department of Biochemistry & Cell Biology, School of Medicine, Kyungpook National University
2012-Present	Health Technology Policy Committee , Ministry of Health & Welfare
2011-Present	Advisory board , Korea National Institute of Health
2011-Present	Bio-Health division , National Science & Technology Commission
2010-2011	Director , KNU Industry-Academic Cooperation Foundation & Research Affair

Featured Corresponding Publications

- Bioengineered protein-based nanocage for drug delivery.** *Advanced Drug Delivery Reviews*, *In press*.
- The phosphatidylserine (PS) receptor stabilin-2 modulates the efficiency of myoblast fusion during myogenic differentiation and muscle regeneration.** *Nat Comm. in press*.
- Prion-like protein “Doppel” is a selective therapeutic target for tumoral angiogenesis.** *J. Clin. Invest.* 2016 Mar 7. pii: 83427. doi: 10.1172/JCI83427. [Epub ahead of print].
- A double-chambered protein nanocage loaded with thrombin receptor agonist peptide (TRAP) and γ -carboxyglutamic acid of protein C (PC-Gla) for sepsis treatment.** *Advanced Materials* 2015, 27 (42), 6637-6643
- Hyaluronic Acid Nanoparticles for Active Targeting Atherosclerosis** *Biomaterials.* 2015 Jun;53:341-8.
- Transforming growth factor β -induced protein promotes severe vascular inflammatory responses,** *Am. J. Respiratory and Critical Care Med.*, 2014 Apr 1;189(7):779-86
- Complex adaptive therapeutic strategy (CATS) for cancer.** *J Control Release.* 2014 Feb 10;175:43-7.
- A Designed Nanocage Displaying Ligand-Specific Peptide Bunches for High Affinity and Biological**

Activity. *ACS Nano*. 2013 Sep 24;7(9):7462-71.

Multiple FAS1 domains and the RGD motif of TGFBI act cooperatively to bind $\alpha\beta3$ integrin, leading to anti-angiogenic and anti-tumor effects. *Biochim Biophys Act-Molecular Cell Research*. 2013 Oct;1833(10):2378-88.

FAS1-domain protein inhibits VEGF165-induced angiogenesis by targeting the interaction between VEGFR-2 and $\alpha\beta3$ integrin. *Mol Cancer Res*. 2012 Aug;10(8):1010-20.

Cross-talk between engulfment receptors, stabilin-2 and integrin $\alpha\beta5$ orchestrates engulfment of phosphatidylserine exposed erythrocytes, *Mol Cell Biol*. 2012 Jul;32(14):2698-708.

Extracellular low pH modulates phosphatidylserine-dependent phagocytosis in macrophages by increasing stabilin-1 expression. *J Biol Chem*. 2012 Mar 30;287(14):11261-71.

Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand. *J Control Release*. 2011 Oct 30;155(2):211-7.

Mechanism for phosphatidylserine-dependent erythrophagocytosis in mouse liver. *Blood*. 2011 May 12;117(19):5215-23.

The conserved histidine in Epidermal Growth Factor-like domains of Stabilin-2 modulates pH dependent recognition of phosphatidylserine in apoptotic cells. *Int J Biochem Cell Biol*. 2010 Jul;42(7):1154-63.

Stabilin-1 mediates phosphatidylserine-dependent clearance of cell corpses in alternatively activated macrophages. *J Cell Sci*. 2009 Sep 15;122(Pt 18):3365-73.

Transforming growth factor-beta-induced protein (TGFBIp/beta ig-h3) activates platelets and promotes thrombogenesis. *Blood*. 2009 Dec 10;114(25):5206-15.